NextPharma is a leading European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with a current footprint spanning five sites in Germany, two in France and one in Finland, one in the United Kingdome and with healthcare logistics services in the DACH region. NextPharma supplies products globally, with eight of its nine sites FDA-approved.
With expertise in solids, semi solids and non-sterile and sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, sprays and syrups and a wide range of packaging solutions including blow-fill-seal, blisters, bottles, sachets, stick packs and tubes.
With the acquisition of two former Lonza sites in 2021 (Ploermel, France and Edinburgh, UK), we added to our services lipid-based formulations as Soft gel and Liquid filled hard-shell for pharmaceutical, high potent, hormonal, and nutritional products.
NextPharma’s expertise and centers of excellence enable it to provide a unique service offering in certain very specific specialized areas such as hormonal solids and semi-solids, cephalosporins, penicillin’s, narcotics, modified release products, ophthalmics as well as paediatric medicinal products. All sites came with its one analytical service center and provide solutions for all analytical methods. Our experienced over 2,000 employees are highly skilled and offer flexible solution in development, production, and clinical trial supply, for our customer needs.
- Formulation Development and commercialization
- Analytical service
- Clinical trial supply (Phase I to IV)
- CT distribution and Storage
- Regulatory support
- Commercial-scale manufacturing
Overall, we are supporting our clients with a very experienced Team that offers an collaborative work approach and consultative service starting from the formulation development and building up the entire lifecycle of the product, up to the commercial supply.
For more information, please visit www.nextpharma.com
About Clinical Trials Innovation Programme 2022
Clinical Trials Innovation Programme is an invitation-only, premium event bringing together a mix of clinical research professionals and service providers in one stimulating environment.
Join us face to face to learn from the best in the drug development industry and have an opportunity to learn from their experiences. With an agenda covering the future of Clinical trials and drug development post COVID, Clinical Trials Innovation Programme 2022 will feature tailored sessions presented by the leading experts from across the globe.
We are bringing together the best in the industry to help you learn and grow, and accelerate your drug development journey. The experts will include thought leaders and visionaries from Danish Medicines Agency, Bayer Pharmaceuticals, AstraZeneca The Janssen Pharmaceutical Companies of Johnson & Johnson, Travere Therapeutics, Biogen, Vifor Pharma, Medical Products Agency and much more.